Highlights Tenaya Therapeutics, Inc.

Equities

TNYA

US87990A1060

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
4.68 ^USD	+1.30%		+8.58%	+44.44%

Mar. 20	Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating	MT
Mar. 19	North American Morning Briefing : Stock Futures -2-	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Tenaya Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18	CI
Tenaya Therapeutics, Inc. Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine	Mar. 18	CI
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications	Feb. 26	CI
Tenaya Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Tenaya Therapeutics Gets FDA Clearance For TN-401 Gene Therapy Trial	23-10-26	MT
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy	23-10-26	CI
Tenaya Therapeutics, Inc. Releases New Data for Tn-301 At the 2023 Heart Failure Society of America	23-10-09	CI
Tenaya Therapeutics, Inc. Doses First Patient in the MyPeak-1? Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy	23-10-05	CI
Tenaya Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Tenaya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Tenaya Therapeutics Says US FDA Grants Fast Track Label for Heart Disease Drug Candidate	23-05-02	MT
TENAYA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-08	AQ
Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08	CI
Tenaya Therapeutics Q4 Loss Narrows	23-03-08	MT
Tenaya Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-08	CI
Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data	23-02-13	RE
Tenaya Therapeutics Cleared to Begin Clinical Trial of Potential Genetic Cardiomyopathy Treatment	23-01-09	MT
Tenaya Therapeutics, Inc. announces U.S. Food and Drug Administration provides clearance of its Investigational New Drug application to initiate clinical testing of TN-201	23-01-09	CI
Tenaya Therapeutics Says US FDA Grants Orphan Drug Designation to Gene Therapy TN-401 for Heart Disease	22-11-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Tenaya Therapeutics, Inc.

Equities

TNYA

US87990A1060

Highlights

Filters